Brind.

GLP-1 Drug Market Sees Shifts as Pfizer Withdraws and Lilly Expands

Steady: 1 in the last 7 days Updated thursday

The latest in this situation

  1. Lilly's retatrutide showed superior efficacy compared to Ozempic in trials.
  2. BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
  3. Pfizer has withdrawn from the competitive GLP-1 weight-loss drug market.
  4. Novo Nordisk is developing an investigational therapy involving CagriSema for the treatment of Type 2 Diabetes and obesity.

How it started

11 reports, 4 independent, last reported Oct 8. The briefing below covers this first event.

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Eli Lilly took the lead in the GLP-1 weight-loss drug market in June 2026. Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year. Pfizer withdrew from the competitive GLP-1 weight-loss drug market on October 8, 2026. Separately, Eli Lilly received FDA approval for an extended dosing schedule of EBGLYSS in moderate-to-severe atopic dermatitis.

From yahoo.com, finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The weight loss drug market is projected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies. Eli Lilly's sales of its industry-leading GLP-1 weight-loss drugs rose significantly in the first quarter of 2026. This market growth is supported by continuous innovation and regulatory approvals in the sector.

From yahoo.com

Who's involved

  • Eli Lilly and CompanyLeading the GLP-1 weight-loss drug market and receiving FDA approvals for extended dosing.
  • Novo NordiskIntense competitor to Eli Lilly in the obesity and diabetes drug market.
  • PfizerWithdrew from the competitive GLP-1 weight-loss drug market.
  • AmgenDirect competitor in the GLP-1 and obesity drug markets.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Eli Lilly and CompanySpeculative

    Could see increased revenue from the expanded market reach due to FDA approval for EBGLYSS.

  • Novo NordiskSpeculative

    Might see increased market share in the obesity and diabetes drug market due to competitive launches.

  • PfizerSpeculative

    Could face pressure on revenue due to patent expirations and industry headwinds.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

How it developed

Newest first. Tap a step to see who reported it.
  1. BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Sub-event
  2. Pfizer has withdrawn from the competitive GLP-1 weight-loss drug market.1 source
  3. Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.Sub-event
  4. Pfizer and Eli Lilly are competing for market share in the GLP-1 weight-loss sector.1 source
  5. Eli Lilly takes the lead in the competitive GLP-1 weight-loss drug market.1 source
  6. Eli Lilly takes the lead in the GLP-1 weight-loss drug market.1 source
  7. Novo Nordisk is expanding its market access, with UAE approval preceding UK market entry.Sub-event
  8. Market projections show the weight loss drug market is expected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies.Sub-event
Show 4 earlier steps
  1. Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.Sub-event
  2. Eli Lilly reported compliance status to HRSA and is scheduled to present data at a meeting in Stockholm.Sub-event
  3. Successful FDA and China NMPA approvals for Eli Lilly's drug candidates.1 source
  4. Industry leaders are dominating the branded weight-loss drug market with improved GLP-1 technologies.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story